Vanguard realignment; no Alkermes (NASDAQ: ALKS) shares reported
Rhea-AI Filing Summary
Alkermes PLC Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Alkermes PLC common stock and 0% of the class. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately.
The amendment is a disclosure of ownership status and reorganization-related reporting changes; it does not show any current beneficial ownership or voting/dispositive power by The Vanguard Group over Alkermes PLC common stock.
Positive
- None.
Negative
- None.
Insights
The filing confirms no beneficial ownership by The Vanguard Group.
The filing states Amount beneficially owned: 0 and Percent of class: 0%, indicating Vanguard reports no current beneficial stake in Alkermes PLC common stock. The statement includes the January 12, 2026 realignment language referencing SEC Release No. 34-39538.
Cash-flow treatment and any prior holdings are not disclosed here; subsequent filings by Vanguard subsidiaries may show separate positions if present.
Amendment documents reporting structure changes, not a transaction.
The amendment explains that certain Vanguard subsidiaries now report holdings on a disaggregated basis following an internal realignment under SEC guidance. The filing asserts those subsidiaries pursue the same strategies previously pursued by The Vanguard Group, Inc.
This is a procedural disclosure about reporting attribution; it does not state any sale, acquisition, or change in Alkermes PLC ownership amount in this excerpt.
FAQ
Does The Vanguard Group own Alkermes PLC (ALKS) shares according to this filing?
What is the significance of the January 12, 2026 realignment mentioned in the filing?
Does this Schedule 13G/A show any recent purchases or sales of ALKS by Vanguard?
Who signed the amendment on behalf of Vanguard and when?
Will separate filings from Vanguard subsidiaries show Alkermes holdings?